Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/DMT/Palliative & End-of-Life Distress

DMT for Palliative & End-of-Life Distress

5 papers and 0 clinical trials exploring dmt as a treatment for palliative & end-of-life distress.

CompoundTryptamine

DMT

A powerful, short-acting tryptamine psychedelic found in many botanical sources, known for rapid onset and intense subjective experiences.

Full DMT profile
IndicationApproximately 40% of patients with terminal illnesses report significant distress at the end of life.

Palliative & End-of-Life Distress

Palliative and end-of-life distress represents a significant psychosocial challenge faced by patients with life-limiting illnesses, significantly impacting quality of life. Recent research suggests that psychedelic compounds, particularly psilocybin, may offer promising therapeutic benefits in alleviating existential distress and improving psychological well-being in these patients.

Full Palliative & End-of-Life Distress profile

Academic Research

5 papers
Open Accessindividual

Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying

In a large online survey of 3,192 people who had either psychedelic-occasioned or non-drug near-death/other non-ordinary experiences that changed their beliefs about death, both types produced comparable reductions in fear of death and high ratings of personal meaning and positive persisting effects, although psychedelic experiences elicited stronger mystical/near-death subjective features while non-drug events were more often rated the single most meaningful life event. Among psychedelics, ayahuasca and DMT tended to produce stronger and more positive enduring consequences than psilocybin and LSD; the authors suggest these characterisations support prospective psychedelic administration studies.

Published
August 24, 2022
Journal
PLOS ONE
Authors
Swee, M. B., Nayak, S., Hurwitz, E., Swift, T. C., Griffiths, R. R.
Paywallmeta

New insights into the clinical and nonclinical effects of psychedelic substances: An integrative review.

This review (2022) explores the potential of psychedelics in treating mental health disorders, their short- and long-term effects on recreational users, and the neurological and cognitive processes responsible for their effects using the most up to date research. The positive findings of psilocybin for depression (MDD) and anxiety are highlighted. The mystical experience (MEQ) also plays a large role, but individual differences (for whom does it work) are still not well examined.

Published
May 23, 2022
Journal
European Psychologist
Authors
Forstmann, M., Sagioglou, C.
Open Accessindividual

Neurochemical models of near-death experiences: A large-scale study based on the semantic similarity of written reports

This large-scale data-analytic study compared the semantic similarity of psychoactive trip reports (n≈15,000) and narrative accounts Near-Death Experiences (n=625), and found that ketamine (followed by salvinorin A and DMT) bared the most resemblance to the experience of 'dying'. The authors speculate that a ketamine model of Near-Death Experiences may indicate a neuroprotective function of endogenous NMDA antagonists released in the proximity of death.

Published
March 1, 2019
Journal
Consciousness and Cognition
Authors
Martial, C., Cassol, H., Charland-Verville, V, Erowid, E., Pallavicini, C., Sanz, C., Vivo, R. M, Zamberlan, F., Erowid, F., Laureys, S., Greyson, B., Tagliazucchi, E.
Open Accessindividual

DMT models the near-death experience

This within-subjects, placebo-controlled study (n=13) found that the DMT experience had many overlaps with the near-death experience (NDE).

Published
August 15, 2018
Journal
Frontiers in Psychology
Authors
Timmermann, C., Roseman, L., Williams, L., Erritzoe, D., Martial, C., Cassol, H., Laureys, S., Nutt, D. J., Carhart-Harris, R. L.
Open Accessmeta

Psychedelics

This paper is the most comprehensive review of psychedelics research up to 2016 by the eminent David E. Nichols.

Published
April 1, 2016
Journal
Pharmacological Reviews
Authors
Nichols, D. E.

Clinical Trials

0 trials

No clinical trials have been tagged with both DMT and Palliative & End-of-Life Distress yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all DMT papers Search all Palliative & End-of-Life Distress trials Full DMT profile Full Palliative & End-of-Life Distress profile